Pharming Group (NASDAQ:PHAR) Shares Gap Down to $8.49

Pharming Group (NASDAQ:PHAR)’s share price gapped down prior to trading on Monday . The stock had previously closed at $8.49, but opened at $8.25. Pharming Group shares last traded at $8.25, with a volume of 220 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Thursday.

Pharming Group Price Performance

The company has a 50 day moving average of $7.79 and a two-hundred day moving average of $8.85. The firm has a market cap of $555.59 million, a P/E ratio of -53.06 and a beta of 0.14. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same quarter last year, the business posted $0.02 EPS. Sell-side analysts expect that Pharming Group will post -0.15 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.